Overview

Update
IPO / Stock
Went Public on Nov 4, 2014 / SIX:MOLN
Total Equity Funding
$59.76M in 2 Rounds from 5 Investors
Headquarters:
Zürich
Description:
Molecular Partners focuses on therapeutic, diagnostic, and biotechnological applications of designed ankyrin repeat proteins.
Founders:
Categories:
Pharmaceutical, Biotechnology, Medical
Website:
http://www.molecularpartners.com

Company Details

Update

Molecular Partners AG, a biotechnology company, engages in the discovery and development of Designed Ankyrin Repeat Proteins (DARPins) based on the designed repeat protein technology. The company focuses on therapeutic, diagnostic, and biotechnological applications of DARPins. DARPins are binding proteins that show activity against various disease targets, including cell surface receptors, cytokines, proteases, kinases, and viral coat proteins. The company was incorporated in 2004 and is based in Zurich, Switzerland.

Funding Rounds (2) - $59.76M

Update
DateAmount / RoundValuationLead InvestorInvestors
Dec, 2009$44.2M / Series B5
Aug, 2007$15.56M / Series A4

Current Team (4)

Update

Offices/Locations (1)

Update
  • Office

    Wagistrasse 14

    Zürich-Schlieren

    Zürich, 8952

    CHE

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos